Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein.
IL-18 is an important cytokine in autoimmune and inflammatory diseases through the induction of IFN-gamma, TNF-alpha, and IL-1. We report herein that collagen-induced arthritis (CIA) in mice is inhibited by treatment with murine IL-18 binding protein (mIL-18BP). CIA was induced in DBA/1J mice by the injection of bovine type II collagen (CII) in IFA with added Mycobacterium tuberculosis on days 0 and 21. The mice were then treated for 3 wk with PBS or with two doses of mIL-18BP (0.5 and 3 mg/kg) as a fusion protein with the Fc portion of murine IgG1. Both the clinical disease activity scores and the histological scores of joint damage were reduced 50% in mice treated with either dose of mIL-18BP. Proliferation of CII-stimulated spleen and lymph node cells as well as the change in serum levels of IgG1 and IgG2a Ab to collagen between days 21 and 42 were decreased in mice treated with mIL-18BP. The production of IFN-gamma, TNF-alpha, and IL-1beta in cultured spleen cells was reduced by in vivo treatment with low dose, but not high dose, mIL-18BP. FACS analysis showed a slight decrease in NK cells and an increase in CD4(+) T cells in spleens of mice treated with mIL-18BP. The steady state mRNA levels of IFN-gamma, TNF-alpha, and IL-1beta in isolated joints were all decreased in mice treated with both doses of mIL-18BP. The mechanisms of mIL-18BP inhibition of CIA include reductions in cell-mediated and humoral immunity to collagen as well as decreases in production of proinflammatory cytokines in the spleen and joints.
Banda
Nirmal K
NK
Division of Rheumatology, Health Sciences Center, University of Colorado School of Medicine, 4200 East Ninth Avenue, Denver, CO 80262, USA.
Vondracek
Andrea
A
Kraus
Damian
D
Dinarello
Charles A
CA
Kim
Soo-Hyun
SH
Bendele
Alison
A
Senaldi
Giorgio
G
Arend
William P
WP
D000818:Animals; D001169:Arthritis, Experimental / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D002358:Cartilage, Articular / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D002417:Cattle; D002452:Cell Count; D003094:Collagen / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000276:immunology*; D006023:Glycoproteins / Q000502:physiology* / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000096:biosynthesis; D036341:Intercellular Signaling Peptides and Proteins; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D020382:Interleukin-18 / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000276:immunology; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000166:cytology; D008264:Macrophages / Q000166:cytology; D051379:Mice; D008811:Mice, Inbred DBA; D012333:RNA, Messenger / Q000032:analysis / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics
D006023:Glycoproteins; D007074:Immunoglobulin G; D036341:Intercellular Signaling Peptides and Proteins; D007375:Interleukin-1; D020382:Interleukin-18; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C118370:interleukin-18 binding protein; D003094:Collagen